to page content
to site navigation
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid
and sustained developers. He currently serves as Chairman of the Boards of Pharmasset, and is a member of the Boards of Directors of Catalyst Biosciences, DepoMed (Amex: DMI), Targacept (NASDAQ: TRGT), Proventys and Phytomedics. Prior to
founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide. In 2002, Mr.
Burrill was recognized as the biotech investment visionary by the prestigious Scientific American magazine (The Scientific American 50). Mr. Burrill is a founder of the Foundation for the National Medals of Science and Technology and
currently serves on its Board of Directors. Some of his not for profit activities include serving on the Boards of Directors for the Bay Area Science Infrastructure Consortium, BayBio, the California Healthcare Institute, the
Exploratorium, The Kellogg Center for Biotechnology, Research America, Campaign for Medical Research, The National Health Museum, and the University of California, San Francisco (UCSF) Foundation. He is also the Chairman of the Mayor's
Biotech Advisory Committee (MAYBAC).
Steve Burrill, CEO of Burrill &amp; Co., provides an overview of the life sciences industry, reflecting on insights he has gained throughout his career. Along the way, he shares his laws of survival and anecdotes that relate the keys to his success in the areas of biotechnology, venture capital and merchant banking.
Brook Byers has been a venture capital investor since 1972. He has been closely involved with more than forty new technology based ventures, over half of which have already become public companies. He formed the first
Life Sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors. KPCB has invested in and helped build over 90 Life Sciences
companies which are developing hundreds of products to treat major underserved medical needs representing huge markets in the nearly two trillion dollar healthcare sector. Brook was the founding President and then Chairman of four
biotechnology companies which were incubated in KPCB's offices and went on to become public companies with an aggregate market value over $8 Billion. He is currently on the Board of Directors of eight companies, most recently joining
CardioDX, Genomic Health Incorporated, Five Prime Therapeutics, Nanofluidics and XDx, Inc.. He was formerly a Director of Idec Pharmaceuticals (Chairman), Athena Neurosciences (Chairman), Signal Pharmaceuticals, Arris Pharmaceuticals,
Pharmacopeia, Ligand Pharmaceuticals (Chairman), Hybritech (Chairman), Genprobe, Nanogen, and others. These companies have pioneered the medical uses of molecular biology, monoclonal antibodies, molecular diagnostics and genomics. Brook
was President and a Director of the Western Association of Venture Capitalists and is a contributing author to the book "Guide to Venture Capital". He is currently a Board member of the University of California at San Francisco Medical
Foundation, the California Healthcare Institute, the New Schools Foundation, Stanford's Bio-X Advisory Council, the Stanford Eye Council and TechNet. He is Co-Chair of the current five year, $1.4 billion, UCSF Capital Campaign. He was
formerly a Director of the Entrepreneurs Foundation, t
Tom Byers is a professor at Stanford University where he focuses on high-technology entrepreneurship education. He is founder and a faculty director of the Stanford Technology Ventures Program (STVP), which serves as the
entrepreneurship center for the engineering school. STVP includes the Mayfield Fellows work/study program, Educators Corner website of teaching resources, and global Roundtable on Entrepreneurship Education conferences. Tom is also a
faculty director of the AEA/Stanford Executive Institute, a general management program for technology executives. Tom is co-author of the textbook called "Technology Ventures: From Idea to Enterprise" (McGraw-Hill, 2005). Tom also holds a
visiting professor appointment at the London Business School and University College London. Tom currently serves as a director on the boards of Reactivity and Flywheel Ventures. In addition, he serves on advisory boards or committees of
the American Society for Engineering Education's Entrepreneurship Division, Harvard Business School's California Research Center, and the National Foundation for Teaching Entrepreneurship (NFTE) for inner-city youth. Previously, Tom
lectured at the Haas School of Business at the University of California, Berkeley. Tom has a range of business experience including executive vice president of Symantec Corporation and founder/president of Slate Corporation. Tom started
his professional career at Accenture. For his efforts at Stanford, Tom holds an endowed chair known as the McCoy University Fellow in Undergraduate Education. Tom was given the 2005 Gores Award for excellence in teaching (the university's
highest award) and the 2002 Tau Beta Pi Award for excellence in undergraduate teaching (the engineering school's highest award). He is a recipient of three recent national teaching awards: the 2005 ASEE Kauffman Award for excellence in
engineering and technology entrepreneurship
Stanford University professor, Tom Byers, discusses ten enduring success factors of high-technology entrepreneurship, including planning, teamwork, venture financing, leadership, cash flow, market positioning, partnerships, and identifying business opportunities.
Prominent industry leaders team up with Stanford Faculty to discuss entrepreneurial solutions to problems in the areas of international affairs, human health and the environment. They tackle world issues from a global and technical perspective beyond the usual bureaucratic approach with a special focus on developing nations.
When Frieda Caplan went into business for herself, she was the only woman in the produce industry. That gave her a national presence, but the real reason for her success was that her company filled an important niche. Now it's the leading distributor of specialty fruits and vegetables. Along the way, the founder learned some important lessons about financing. And she's still going to work every day-with her daughters.
For the past several years, Alex Cappello has devoted most of his time to an organization supporting entrepreneurship worldwide.
Learn how a clearly defined brand identity can help build your business, even in the face of fierce competition.
What are the chances that, out of thousands of candidates for the CEO spot, the son or daughter of the company founder is the most competent of the bunch? Slim to none.
Say you are a member of the Ford family, and your financial security lay in family trusts stuffed with Ford Motor stock. Who would you rather bet on, William Clay Ford Jr. or Alan Mulally, the former Boeing exec now at Ford's wheel? In this case, Mulally had the presence of mind to secure $24 billion in funding prior to the recent economic collapse and thus avoided becoming a ward of the federal government, like GM and Chrysler.
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.